View in EDS HTML Full Text PDF Full Text

Association Study of the Dihydropyrimidinase-Related Protein 2 Gene and Methamphetamine Psychosis.

Saved in:
Bibliographic Details
Title: Association Study of the Dihydropyrimidinase-Related Protein 2 Gene and Methamphetamine Psychosis.
Authors: UJIKE, H.1,2 (AUTHOR), SAKAI, A.3 (AUTHOR), NAKATA, K.4 (AUTHOR), TANAKA, Y.1 (AUTHOR), KODAKA, T.1 (AUTHOR), OKAHISA, Y.1 (AUTHOR), HARANO, M.2,5 (AUTHOR), INADA, T.2,6 (AUTHOR), YAMADA, M.2,7 (AUTHOR), KOMIYAMA, T.2,8 (AUTHOR), HORI, T.2,8 (AUTHOR), SEKINE, Y.2,9 (AUTHOR), IWATA, N.2,10 (AUTHOR), SORA, I.2,11 (AUTHOR), IYO, M.2,12 (AUTHOR), OZAKI, N.2,13 (AUTHOR), KURODA, S.1 (AUTHOR)
Source: Annals of the New York Academy of Sciences. 2006, Vol. 1074 Issue 1, p90-96. 7p. 2 Charts.
Subjects: Methamphetamine, Substance abuse, Psychoses, Schizophrenia, Genetic polymorphisms, Japanese people, Population
Abstract: Dihydropyrimidinase-related protein 2 (DRP-2 or DPYSL-2)mediates the intracellular response to collapsin, a repulsive extracellular guidance cue or axonal outgrowth. DRP-2 is also referred to as collapsin response mediator protein 2 (CRMP-2). We have previously demonstrated that the DRP-2 gene is associated with susceptibility to schizophrenia, but not to bipolar disorders. In addition, a genetic association was observed with paranoid-type schizophrenia, but not with hebephrenic-type schizophrenia. It has been well documented that repeated abuse of methamphetamine (METH) for a long period frequently produces psychotic symptoms, such as auditory hallucinations and delusions that are hardly distinguishable from those of paranoid-type schizophrenia. Therefore, we hypothesized that a certain genetic variant of the DRP-2 gene may affect individual vulnerability to the development of METH-induced psychosis. We examined the genetic association by a case–control method. The polymorphism *2236T>C in the 3′ untranslated region of the DRP-2 gene, which has been shown to be a negative genetic risk factor for paranoid-type schizophrenia, was analyzed in 198 patients with METH psychosis and 221 corresponding healthy controls in a Japanese population. No significant association of the DRP-2 gene with METH psychosis was found. Neither did we find an association with the clinical phenotype of METH psychosis, such as the age of first consumption of METH, latency to development of psychosis after METH abuse, prognosis of psychosis after detoxification from METH use, complication of spontaneous relapse of psychosis without reconsumption of the drug, or multisubstance abuse status. These findings indicate that a genetic variant of the DRP-2 gene may not affect the risk of METH psychosis or any clinical phenotype of the disorder. [ABSTRACT FROM AUTHOR]
Copyright of Annals of the New York Academy of Sciences is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Engineering Source
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: egs
DbLabel: Engineering Source
An: 22419672
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Association Study of the Dihydropyrimidinase-Related Protein 2 Gene and Methamphetamine Psychosis.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22UJIKE%2C+H%2E%22">UJIKE, H.</searchLink><relatesTo>1,2</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22SAKAI%2C+A%2E%22">SAKAI, A.</searchLink><relatesTo>3</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22NAKATA%2C+K%2E%22">NAKATA, K.</searchLink><relatesTo>4</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22TANAKA%2C+Y%2E%22">TANAKA, Y.</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22KODAKA%2C+T%2E%22">KODAKA, T.</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22OKAHISA%2C+Y%2E%22">OKAHISA, Y.</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22HARANO%2C+M%2E%22">HARANO, M.</searchLink><relatesTo>2,5</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22INADA%2C+T%2E%22">INADA, T.</searchLink><relatesTo>2,6</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22YAMADA%2C+M%2E%22">YAMADA, M.</searchLink><relatesTo>2,7</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22KOMIYAMA%2C+T%2E%22">KOMIYAMA, T.</searchLink><relatesTo>2,8</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22HORI%2C+T%2E%22">HORI, T.</searchLink><relatesTo>2,8</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22SEKINE%2C+Y%2E%22">SEKINE, Y.</searchLink><relatesTo>2,9</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22IWATA%2C+N%2E%22">IWATA, N.</searchLink><relatesTo>2,10</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22SORA%2C+I%2E%22">SORA, I.</searchLink><relatesTo>2,11</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22IYO%2C+M%2E%22">IYO, M.</searchLink><relatesTo>2,12</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22OZAKI%2C+N%2E%22">OZAKI, N.</searchLink><relatesTo>2,13</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22KURODA%2C+S%2E%22">KURODA, S.</searchLink><relatesTo>1</relatesTo> (AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Annals+of+the+New+York+Academy+of+Sciences%22">Annals of the New York Academy of Sciences</searchLink>. 2006, Vol. 1074 Issue 1, p90-96. 7p. 2 Charts.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Methamphetamine%22">Methamphetamine</searchLink><br /><searchLink fieldCode="DE" term="%22Substance+abuse%22">Substance abuse</searchLink><br /><searchLink fieldCode="DE" term="%22Psychoses%22">Psychoses</searchLink><br /><searchLink fieldCode="DE" term="%22Schizophrenia%22">Schizophrenia</searchLink><br /><searchLink fieldCode="DE" term="%22Genetic+polymorphisms%22">Genetic polymorphisms</searchLink><br /><searchLink fieldCode="DE" term="%22Japanese+people%22">Japanese people</searchLink><br /><searchLink fieldCode="DE" term="%22Population%22">Population</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: Dihydropyrimidinase-related protein 2 (DRP-2 or DPYSL-2)mediates the intracellular response to collapsin, a repulsive extracellular guidance cue or axonal outgrowth. DRP-2 is also referred to as collapsin response mediator protein 2 (CRMP-2). We have previously demonstrated that the DRP-2 gene is associated with susceptibility to schizophrenia, but not to bipolar disorders. In addition, a genetic association was observed with paranoid-type schizophrenia, but not with hebephrenic-type schizophrenia. It has been well documented that repeated abuse of methamphetamine (METH) for a long period frequently produces psychotic symptoms, such as auditory hallucinations and delusions that are hardly distinguishable from those of paranoid-type schizophrenia. Therefore, we hypothesized that a certain genetic variant of the DRP-2 gene may affect individual vulnerability to the development of METH-induced psychosis. We examined the genetic association by a case–control method. The polymorphism *2236T>C in the 3′ untranslated region of the DRP-2 gene, which has been shown to be a negative genetic risk factor for paranoid-type schizophrenia, was analyzed in 198 patients with METH psychosis and 221 corresponding healthy controls in a Japanese population. No significant association of the DRP-2 gene with METH psychosis was found. Neither did we find an association with the clinical phenotype of METH psychosis, such as the age of first consumption of METH, latency to development of psychosis after METH abuse, prognosis of psychosis after detoxification from METH use, complication of spontaneous relapse of psychosis without reconsumption of the drug, or multisubstance abuse status. These findings indicate that a genetic variant of the DRP-2 gene may not affect the risk of METH psychosis or any clinical phenotype of the disorder. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of Annals of the New York Academy of Sciences is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=egs&AN=22419672
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1196/annals.1369.008
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 7
        StartPage: 90
    Subjects:
      – SubjectFull: Methamphetamine
        Type: general
      – SubjectFull: Substance abuse
        Type: general
      – SubjectFull: Psychoses
        Type: general
      – SubjectFull: Schizophrenia
        Type: general
      – SubjectFull: Genetic polymorphisms
        Type: general
      – SubjectFull: Japanese people
        Type: general
      – SubjectFull: Population
        Type: general
    Titles:
      – TitleFull: Association Study of the Dihydropyrimidinase-Related Protein 2 Gene and Methamphetamine Psychosis.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: UJIKE, H.
      – PersonEntity:
          Name:
            NameFull: SAKAI, A.
      – PersonEntity:
          Name:
            NameFull: NAKATA, K.
      – PersonEntity:
          Name:
            NameFull: TANAKA, Y.
      – PersonEntity:
          Name:
            NameFull: KODAKA, T.
      – PersonEntity:
          Name:
            NameFull: OKAHISA, Y.
      – PersonEntity:
          Name:
            NameFull: HARANO, M.
      – PersonEntity:
          Name:
            NameFull: INADA, T.
      – PersonEntity:
          Name:
            NameFull: YAMADA, M.
      – PersonEntity:
          Name:
            NameFull: KOMIYAMA, T.
      – PersonEntity:
          Name:
            NameFull: HORI, T.
      – PersonEntity:
          Name:
            NameFull: SEKINE, Y.
      – PersonEntity:
          Name:
            NameFull: IWATA, N.
      – PersonEntity:
          Name:
            NameFull: SORA, I.
      – PersonEntity:
          Name:
            NameFull: IYO, M.
      – PersonEntity:
          Name:
            NameFull: OZAKI, N.
      – PersonEntity:
          Name:
            NameFull: KURODA, S.
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 09
              Text: 2006
              Type: published
              Y: 2006
          Identifiers:
            – Type: issn-print
              Value: 00778923
          Numbering:
            – Type: volume
              Value: 1074
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Annals of the New York Academy of Sciences
              Type: main
ResultId 1